Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Recruiting 9Unknown 8Completed 7Not yet recruiting 4Active not recruiting 2

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 78Colorectal Neoplasms 53Breast Neoplasms 53Neoplasms 40Advanced Solid Tumors 33Prostatic Neoplasms 31Multiple Myeloma 31Neoplasm Metastasis 29Recurrence 28Ovarian Neoplasms 28Lung Neoplasms 28Carcinoma, Hepatocellular 28Pancreatic Neoplasms 26Advanced Solid Tumor 21Small Cell Lung Carcinoma 20Leukemia, Myeloid, Acute 20Melanoma 18Endometrial Neoplasms 18Triple Negative Breast Neoplasms 17Lymphoma, Follicular 15Squamous Cell Carcinoma of Head and Neck 14Stomach Neoplasms 13Lymphoma, B-Cell 13Glioma 13Uterine Cervical Neoplasms 12Head and Neck Neoplasms 12Glioblastoma 12Lymphoma 11Solid Tumor 10Myasthenia Gravis 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Not yet recruiting × INDUSTRY × Advanced Malignant Tumors × Clear all
NCT07338838 2026-01-14

To Evaluate the Tolerability and Pharmacokinetics of TQB3142 for Injection in Patients With Advanced Malignant Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Not yet recruiting
66 enrolled

Advanced Malignant Tumors

NCT06770881 2025-01-13

JSKN033 in Chinese Subjects with Advanced Malignant Tumors

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1/2 Not yet recruiting
430 enrolled

Advanced Malignant Tumors

NCT06691360 2024-11-15

AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant Tumors

Akeso

Phase 1 Not yet recruiting
87 enrolled

Advanced Malignant Tumors

NCT06226363 2024-01-26

Phase I Study of LNF1901 in Advanced Malignant Tumors

Shandong New Time Pharmaceutical Co., LTD

Phase 1 Not yet recruiting
82 enrolled

Advanced Malignant Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡